TL938

· Suzhou Teligene Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TL938, covering 2025-05-15 to 2025-05-15. Get the full timeline:

Most recent: Clinical Trial Update: TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer [Phase 2]